• Top page
  • Timetable
  • Per session
  • Per presentation
  • How to
  • Meeting Planner



Integrated Symposium of Basic and Clinical Neuroscience:Inducued pluripotent stem (iPS) cells: from basic research to clinical application

開催日 2014/9/11
時間 9:00 - 11:00
会場 Room A(Main Hall)
Chairperson(s) 髙橋 良輔 / Ryosuke Takahashi (京都大学大学院医学研究科・臨床神経学 / Department of Neurology, Kyoto University Graduate School of Medicine, Japan)
岡野 栄之 / Hideyuki Okano (慶應義塾大学医学部 / Department of Physiology, Keio University School of Medicine, Japan)

iPSCs technology: its application for regenerative medicine and diseases modeling

  • S1-A-1-1
  • 岡野 栄之 / Hideyuki Okano:1 
  • 1:慶應義塾大学医学部 / Keio University School of Medicine, Japan 

The induced pluripotent stem cells (iPSCs) technology is attracting an increasing attention for their application for medical science, from the aspects of regenerative medicine (cell therapy) and disease modeling. As regards the application for regenerative medicine, we have been developing iPSC-based cell therapy for spinal cord injury (SCI) using human iPSCs-derived neural stem/progenitor cells (hiPSC-NS/PCs). So far we could induce a long term functional recovery of rodent and non-human primate SCI model using hiPSC-NS/PCs (Nori et al., PNAS, 2011; Okano et al. Cir Res, 2014). The roadmap for the clinical application will be shown in the talk.
iPSCs technology also contributes to recapitulate the phenotypes of neurological diseases and broaden our understanding of the pathogenesis of many psychiatric and neurological diseases, including those of psychiatric diseases (Bundo et al., Neuron, 2014), pediatric (Higurashi et al., Mol Brain, 2013; Kuroiwa-Numasawa et al. Stem Cell Rep, 2014) and late onset (Yagi et al., Human Mol Genet, 2011; Ito et al., Annals of Neurol, 2012; Imaizumi et al., Mol Brain, 2012; Nihei et al., J. Biol. Chem, 2013; Imaizumi and Okano, J Neurochem, 2014). These diseases can be subclassified into diseases caused by abnormal gene regulations, those with structural abnormalities of nervous systems, those with abnormal neural functions and those abnormal genes functions. Through these observations, we conclude that characterization of iPSCs derived from pediatric neurological disorders could recapitulate the diseases processes at least partially and that characterization of iPSCs from late onset neurological disorders could predict the diseases-related accumulation of abnormal deposits, metabolic abnormalities and morphological changes of organelle in vitro at a certain culture condition at a relatively short period. Thus, iPSCs technology provides an opportunity for preemptive treatments for these late onset diseases.

Copyright © Neuroscience2014. All Right Reserved.